武漢大眾口腔醫療股份有限公司 章程 1 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | 5 | | 第一節 | 股份發行 | 5 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 9 | | 第四章 | 股東和股東會 | 9 | | 第一節 | 股東 | 9 | | 第二節 | 股東會的一般規定 | 16 | | 第三節 | 股東會的召集 | 20 | | 第四節 | 股東會的提案與通知 | 22 | | 第五節 | 股東會的召開 | 24 | | 第六節 | 股東會的表決和決議 | 28 | | 第五章 | 董事會 | 34 | | 第一節 | 董事 | 34 | | 第二節 | 董事會 | 37 | | 第六章 | 總經理及其他高級管理人員 | 43 | | 第七章 | 監事會 | 46 | | 第一節 | 監事 | 46 | | 第二節 | 監事會 | 47 | | 第八章 | 財務會計制度、利潤分配和審計 | 49 | | 第一節 | 財務會計制度 | 49 | | 第二節 | ...

（股份代號：2651） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 修訂公司章程 本公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則第13.51(1)條作 出。 茲提述武漢大眾口腔醫療股份有限公司（「本公司」）日期為2025年6月30日的招股 章程（「招股章程」）以及日期分別為2025年7月8日及2025年8月4日的公告。除另 有界定外，本公告所用詞彙與招股章程所界定者具有相同涵義。 為反映本公司全球發售及超額配股權失效後本公司註冊股本及股本結構的有關變 更，根據本公司於2024年11月22日舉行的2024年第二次臨時股東會作出的授權， 及經董事會批准，本公司已根據全球發售的完成情況，對本公司的公司章程（「公 司章程」）作出相應修訂。 公司章程的修訂詳情如下： | 修訂前條款 | 修訂後 ...

Financial Performance - For the six months ended June 30, 2025, the company's revenue decreased by 9.2% to RMB 185.8 million from RMB 204.5 million for the same period in 2024[8]. - Net profit decreased by 2.2% to RMB 28.6 million for the six months ended June 30, 2025, from RMB 29.2 million for the same period in 2024[8]. - The company reported a revenue of RMB 185,798 thousand for the six months ended June 30, 2025, a decrease of 9.1% compared to RMB 204,549 thousand in the same period of 2024[77]. - The company’s net profit for the period was RMB 28,602 thousand, slightly down from RMB 29,245 thousand in the previous year[77]. - The pre-tax profit for the six months ended June 30, 2025, was RMB 31,603,000, down from RMB 33,851,000 in 2024, reflecting a decline of 6.7%[84]. - Cash flow from operating activities for the six months ended June 30, 2025, was RMB 35,607,000, compared to RMB 45,434,000 in 2024, indicating a decrease of 21.8%[84]. - The company's income tax expense for the six months ended June 30, 2025, was RMB 3,001,000, a decrease of 34.8% from RMB 4,606,000 for the same period in 2024[97]. Profitability Metrics - The gross profit margin increased to 37.8% for the six months ended June 30, 2025, compared to 36.6% for the same period in 2024[8]. - The net profit margin improved to 15.4% for the six months ended June 30, 2025, up from 14.3% for the same period in 2024[8]. - Gross profit for the same period was RMB 70,268 thousand, down from RMB 74,849 thousand, reflecting a gross margin of approximately 37.8%[77]. - Adjusted net profit increased by 13.9% from RMB 30.2 million for the six months ended June 30, 2024, to RMB 34.4 million for the six months ended June 30, 2025[38]. Revenue Breakdown - Comprehensive dental services generated RMB 102.0 million, accounting for 54.9% of total revenue, down from RMB 110.8 million (54.2%) in the previous period[27]. - Implant services revenue fell by 10.5% to RMB 53.6 million, representing 28.8% of total revenue, compared to RMB 59.8 million (29.3%) previously[28]. - Orthodontic services revenue decreased by 10.9% to RMB 30.2 million, making up 16.3% of total revenue, down from RMB 33.9 million (16.5%) in the prior period[29]. Market Overview - The Chinese dental service market is projected to grow from RMB 147.2 billion in 2024 to RMB 200.4 billion by 2029, at a CAGR of 6.4%[19]. - The Central China dental service market is expected to reach RMB 40 billion by 2029, growing at a CAGR of 6.9% from 2024[19]. - The private dental service market in Central China is anticipated to grow from RMB 16.8% of the total private dental service market in 2024 to RMB 25.3 billion by 2029, with a CAGR of 7.8%[19]. - The company holds a market share of approximately 2.4% among all private dental service providers in Central China as of 2024[19]. Operational Developments - The company opened 8 new dental clinics during the six months ended June 30, 2025, expanding its market presence[8]. - The total number of dental chairs increased by 3.6% to 717 as of June 30, 2025, from 692 as of June 30, 2024[8]. - The total number of patient visits reached 355,181, with 151,998 being new patients during the six months ended June 30, 2025[9]. - The company operates a total of 92 dental institutions, including 4 profit-making dental hospitals and 80 dental clinics, across 8 cities in Hubei and Hunan provinces[11]. - The company focuses on providing comprehensive dental services, including preventive care, treatment of common oral diseases, and orthodontic services[12]. Cost Management - Sales cost decreased by 10.9% from RMB 129.7 million for the six months ended June 30, 2024, to RMB 115.5 million for the six months ended June 30, 2025[30]. - Other income and gains decreased by 64.4% from RMB 3.2 million for the six months ended June 30, 2024, to RMB 1.2 million for the six months ended June 30, 2025[32]. - Selling and distribution expenses decreased by 28.5% from RMB 22.9 million for the six months ended June 30, 2024, to RMB 16.3 million for the six months ended June 30, 2025[33]. - Administrative expenses increased by 14.7% from RMB 14.5 million for the six months ended June 30, 2024, to RMB 16.6 million for the six months ended June 30, 2025[34]. - Financial costs decreased by 12.1% from RMB 2.8 million for the six months ended June 30, 2024, to RMB 2.4 million for the six months ended June 30, 2025[35]. Employee and Shareholder Information - As of June 30, 2025, the company has 1,115 employees, a decrease from 1,164 employees as of December 31, 2024, with employee benefits expenses amounting to RMB 75.4 million for the six months ended June 30, 2025[52]. - The company confirmed RMB 0.9 million in share-based payment expenses under the employee incentive plan for the six months ended June 30, 2025[52]. - The company has adopted a pre-IPO restricted share plan to incentivize senior staff, with a total of 5,750,740 restricted shares reserved for this purpose[53]. - As of June 30, 2025, the total issued shares amount to 49,379,042, including 17,026,140 H shares and 32,352,902 non-listed shares[57]. - Mr. Yao holds 31,324,102 non-listed shares, representing 63.44% of the total issued shares, and has a beneficial interest in 475,800 non-listed shares[55]. Corporate Governance - The company did not declare any interim dividends during the reporting period[69]. - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial performance for the six months ending June 30, 2025[71]. - The company has complied with applicable laws and regulations during the reporting period, including the Hong Kong Companies Ordinance and the Listing Rules[68]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[67].

Core Viewpoint - The company, Dazhong Oral (02651.HK), announced a board meeting scheduled for August 29, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential distribution of an interim dividend, if any [1] Group 1 - The board meeting will take place on August 29, 2025 [1] - The meeting will focus on the approval of the company's interim results for the six months ending June 30, 2025 [1] - The company will also consider the distribution of an interim dividend during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 武漢大眾口腔醫療股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公 司將於2025年8月29日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年6月30日止六個月的中期業績及其發佈，並考慮派 發中期股息（如有）。 承董事會命 武漢大眾口腔醫療股份有限公司 董事長兼執行董事 姚雪先生 中國湖北省武漢 2025年8月18日 於本公告日期，本公司董事會包括(i)執行董事姚雪先生、沈洪敏女士、郭家平先 生及劉紅嬋女士；及(ii)獨立非執行董事疏義傑先生、黃素珍女士及王陶沙女士。 Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2651） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 ...

Core Viewpoint - The stabilization period for the global offering of Dazhong Oral (02651) ended on August 3, 2025, with no over-allotment of shares confirmed by the sole global coordinator [1] Group 1 - The stabilization price period concluded 30 days after the deadline for submitting the Hong Kong public offering application [1] - The company did not exercise the over-allotment option, which has now lapsed [1] - The stabilization agent reported that no stabilization actions were taken during the stabilization price period [1]

Core Viewpoint - The global offering's stabilization period for Dazhong Oral (02651.HK) ended on August 3, 2025, with no over-allotment of shares confirmed by the exclusive overall coordinator [1] Summary by Relevant Sections - **Stabilization Period** The stabilization period for the global offering has concluded as of August 3, 2025, which is 30 days after the deadline for submitting the application for the Hong Kong public offering [1] - **Over-allotment and Stabilization Actions** The exclusive overall coordinator confirmed that there was no over-allotment of shares in the international offering. Consequently, the over-allotment option was not exercised and has lapsed. Additionally, the stabilization agent informed that no stabilization actions were taken during the stabilization period [1]

Core Viewpoint - The global offering's stabilization period for the company has ended on August 3, 2025, with no over-allotment of shares confirmed by the exclusive overall coordinator [1] Group 1 - The stabilization period concluded 30 days after the submission deadline for the Hong Kong public offering application [1] - The company did not exercise the over-allotment option, and it has now lapsed [1] - The stabilization agent informed that no stabilization actions were taken during the stabilization period [1]

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 除本公告另有界定者外，本公告所用詞彙與武漢大眾口腔醫療股份有限公司（「本公司」）刊發日 期為2025年6月30日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告乃根據香港法例第571W章《證券及期貨（穩定價格）規則》第9(2)條作出。 本公告僅作說明用途，並不構成收購、購買或認購本公司任何證券的要約或誘使作出要約的邀 請。本公告並非招股章程。有意投資者於決定是否投資於發售股份前應閱覽招股章程，以獲得 有關本公司及下文所述全球發售的詳細資料。 本公告概不構成出售要約或要約購買的招攬，而在任何作出有關要約、招攬或出售即屬違法的 司法管轄區內，概不得出售任何發售股份。本公告不會直接或間接於或向美國（包括美國的領 土及屬地、美國任何州以及哥倫比亞特區）發佈、刊發或派發。本公告並不構成亦不屬於在美 國境內或於任何其他司法管轄區購買或認購證券的任何要約或招攬的一部分。發售股份不曾亦 不會 ...